Your Genes, Your GLP-1: 23andMe Links DNA to Weight Loss Success

PALO ALTO, CA – April 08, 2026 – A groundbreaking study published today in the journal Nature by the 23andMe Research Institute provides the first large-scale genetic evidence explaining why the new class of blockbuster weight-loss drugs, known as GLP-1 receptor agonists, produces wildly different results from person to person.

The research, which leveraged the company's massive crowdsourced genetic database, could usher in a new era of precision medicine for obesity, moving treatment beyond the current trial-and-error approach and toward a future where a simple genetic test could help predict a patient's success on medications like Ozempic, Wegovy, and Zepbound.

GLP-1 drugs have transformed the landscape of weight management, but their effectiveness is notoriously variable. While some patients achieve dramatic weight loss exceeding 20% of their body weight, others see minimal results. Similarly, debilitating side effects like nausea and vomiting plague some users while others experience none. The new study pinpoints specific genetic variations that are significantly associated with both the efficacy of these drugs and the likelihood of adverse reactions.

“The study demonstrates the incredible power of our crowdsourced research community to advance scientific understanding of human genetic variation,” said Adam Auton, Vice President of Human Genetics at 23andMe Research Institute and an author of the study, in a statement.

Decoding the GLP-1 Response

To unravel the genetic threads influencing drug response, researchers conducted a genome-wide association study (GWAS) on an unprecedented scale, analyzing data from 27,885 individuals who had self-reported their use of GLP-1 medications.

The findings provide direct evidence for what many clinicians have long suspected: a person's underlying genetics play a crucial role. The research team identified a specific missense variant—a small change in the DNA sequence that alters a protein—in the GLP1R gene, which is the very gene that GLP-1 drugs target. Individuals carrying this variant were found to experience significantly greater weight loss while on the medication.

Furthermore, the study sheds light on the genetic basis of the drugs' most common side effects. Variations in both the GLP1R gene and another related gene, GIPR, were linked to an increased likelihood of experiencing nausea or vomiting. Interestingly, the research uncovered a drug-specific connection: the genetic variation in the GIPR gene was associated with side effects only in individuals using tirzepatide (sold as Mounjaro and Zepbound), which targets both GLP-1 and GIP receptors. This link was not observed in users of semaglutide (Ozempic and Wegovy), which only targets the GLP-1 receptor.

These discoveries lay a critical foundation for tailoring obesity treatment. In the future, a physician could potentially use a patient's genetic profile to select the most effective GLP-1 medication and proactively manage the risk of side effects, fundamentally changing the conversation around weight management.

From Lab to Life: A New Personalized Report

Coinciding with the scientific publication, the 23andMe Research Institute has launched a new report for members of its premium Total Health service. The report, titled "GLP-1 Medications: Weight Loss and Nausea," translates the complex findings from the research into actionable, personalized insights for consumers.

The new tool integrates an individual's genetic data with other factors like age and existing medical conditions to generate a personalized prediction model. According to the institute, this model can predict significant variability in patient outcomes. Among its research participants, estimated weight loss ranged from as little as 6% to as much as 20% of starting body weight, while the probability of experiencing nausea or vomiting varied from 5% to a staggering 78%, all depending on this combination of genetic and clinical factors.

Dr. Noura Abul-Husn, Chief Medical Officer at the 23andMe Research Institute, emphasized the need for a more informed approach. “While there is high interest in GLP-1 medications, there is significant variation in how well they work for different people,” she stated. “The market is crowded with weight loss support and medications, but the approach to weight management is typically one of trial and error. This can lead people to leap into treatment with a high degree of uncertainty and unrealistic expectations.”

Crucially, the report is not a standalone diagnostic. It is provided exclusively through the Total Health service, which includes clinician guidance. “GLP-1 treatment decisions are complex and having access to clinical expertise to help contextualize your genetic results alongside your full health picture is exactly the kind of guidance this report is designed to support,” continued Abul-Husn.

A New Era for a Genomics Pioneer

The announcement comes at a pivotal moment for 23andMe. In a major strategic shift that concluded in mid-2025, the company transitioned its core operations from a publicly traded for-profit entity to a nonprofit public benefit corporation, the 23andMe Research Institute. Led by co-founder Anne Wojcicki, the organization was acquired by the TTAM Research Institute in a move designed to prioritize long-term scientific discovery over shareholder returns.

This new nonprofit structure allows the institute to focus on leveraging its vast database—built from over 12 million customers, more than 80% of whom consented to participate in research—for the public good. The pivot aims to attract philanthropic funding and government grants to accelerate research in areas like drug discovery and disease prediction, a mission that the for-profit model was seen as constraining.

As part of this transition and to address long-standing concerns about data privacy in the genomics space, the institute also established a Privacy Advisory Board composed of independent experts. This move, a condition of the acquisition, signals a renewed commitment to the ethical stewardship of the sensitive genetic data that powers its research engine.

The Dawn of Precision Obesity Treatment

While 23andMe's new report is a pioneering step, it enters an increasingly active field. The broader healthcare industry is rapidly moving toward personalized medicine, with academic institutions and companies like National Integrative Health already exploring pharmacogenomics for "GLP-1 management." However, the scale of 23andMe's dataset provides a distinct advantage in identifying statistically significant genetic links.

The ultimate success of this approach will depend on its adoption by the medical community. While the inclusion of clinician guidance is a critical step, the broader integration of such genetic reports into routine clinical practice remains a future challenge. Physicians will need to be educated on how to interpret these new data points and incorporate them into treatment plans alongside traditional clinical assessments.

Nevertheless, this development marks a significant convergence of big data, consumer genetics, and clinical pharmacology. By beginning to unravel the genetic code behind weight loss drug response, the 23andMe Research Institute is not just publishing a study; it is drawing a new map for navigating obesity treatment. For the millions of patients seeking effective and tolerable solutions, this personalized approach may finally offer a clearer path forward.